Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Blood Oath

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 2

  1. AI short-drama creators trade plagiarism accusations in China

    On Oct 14, AI short-drama creator Magic Xiaomi accused Blood Oath, made by a creator named Angel, of copying her series Trust Tracker, and the two agreed to post evidence two days later on Douyin. On Oct 16 Xiaomi published a roughly 7,000-character post listing 13 side-by-side comparisons, while Angel published 28 image-and-text posts rejecting each point, saying she had never seen Xiaomi's work before the dispute and did not need to copy anyone. Both creators say their scripts are original and that they produce episodes with various AI models and agents, with visuals generated rather than filmed; according to the reports, neither side has produced conclusive evidence on whether Angel had access to the earlier work.

    虎嗅 AI · 🔥 0
  2. Chinese creators' AI-made K-drama and J-drama shorts break out; top hit earns millions

    Tech Planet reports, in a piece republished by TMTPost, that AI-generated short dramas styled after Korean, Japanese and US series are spreading on Douyin and Xiaohongshu, with single episodes drawing tens of thousands to over a million likes. The Korean-style series "Pretty Malice" (漂亮的恶意) launched its first episode on Douyin on August 28 and, according to producer Li Zhenjie, has reached 180 million views across six episodes and earned several million yuan, mainly through advertising on its account rather than platform revenue sharing. The article also cites industry figures showing about 221,900 new AI short dramas on Douyin in the first half of 2026, only about 1,055 passing 100 million views (roughly 0.47%), and fewer than 1.3% recouping costs by industry estimate.

    钛媒体 · 🔥 0

Experience and discussion from the community

Share my Blood Oath experienceAsk about Blood Oath

Nobody has shared their experience with Blood Oath yet.